Butenafine Hydrochloride 1% + Butenafine Hydrochloride 1% B + Butenafine Hydrochloride 1% + Vehicle A + Vehicle B
Phase 1Terminated 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Interdigital Tinea Pedis
Conditions
Interdigital Tinea Pedis
Trial Timeline
Jul 1, 2010 → Jul 1, 2011
NCT ID
NCT01119742About Butenafine Hydrochloride 1% + Butenafine Hydrochloride 1% B + Butenafine Hydrochloride 1% + Vehicle A + Vehicle B
Butenafine Hydrochloride 1% + Butenafine Hydrochloride 1% B + Butenafine Hydrochloride 1% + Vehicle A + Vehicle B is a phase 1 stage product being developed by Sun Pharmaceutical for Interdigital Tinea Pedis. The current trial status is terminated. This product is registered under clinical trial identifier NCT01119742. Target conditions include Interdigital Tinea Pedis.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01119742 | Phase 1 | Terminated |
Other Products from Sun Pharmaceutical
Ilumya Injectable ProductApproved
85
CequaTM (Cyclosporine 0.09%) ophthalmic solutionApproved
85
Cyclosporine + Artificial tearApproved
85
AmifostineApproved
85
Ilaprazole antisecretory drug of each quadruple therapy the Ilaprazole -based quadruple therapy + Esoprazole antisecretory drug of each quadruple therapy Esoprazole-based quadruple therapyApproved
85